Scholar Rock Holding Corporation is a biopharmaceutical company focused on spinal muscular atrophy (SMA) and other rare neuromuscular diseases. Its lead antibody, apitegromab, has positive Phase 3 SAPPHIRE data in non‑ambulatory Type 2/3 SMA, and a resubmitted Biologics License Application was accepted by the FDA with a September 30, 2026 PDUFA action date. A marketing authorization application for SMA is also under review in Europe.
For the six months ended June 30, 2026, the company reported a net loss of $215.4 million, driven by research and development expense of $110.0 million and general and administrative expense of $100.9 million as it builds commercial infrastructure. Cash, cash equivalents and marketable securities totaled $492,088 (thousands), and management expects this to fund operations into the second half of 2027.
During 2026, Scholar Rock strengthened its balance sheet through a new term loan facility with Blue Owl, drawing $200.0 million, and via an at‑the‑market equity program that raised $160.8 million. Key programs include the ONYX long‑term extension in SMA, Phase 2 OPAL in SMA patients under age two, Phase 2 FORGE in FSHD, and a Phase 1 study of SRK‑439.
Scholar Rock reported a Q2 2026 net loss of $109.9 million, or $0.84 per share, with no revenue for the quarter. Research and development expense was $58.2 million and general and administrative expense was $50.7 million. The company ended June 30, 2026 with $492.1 million in cash, cash equivalents, and marketable securities, reflecting $62.8 million of net proceeds from its at-the-market equity program.
The company highlighted regulatory progress for its lead SMA candidate apitegromab. Its Biologics License Application is under FDA review with a September 30, 2026 PDUFA date, supported by two fill-finish facilities and what the company describes as ample commercial supply upon approval. The EMA is reviewing a Marketing Authorisation Application and is awaiting FDA inspection classification of the Catalent Indiana facility, while Scholar Rock discusses adding a second fill-finish site. The U.S. commercial team is preparing for launch, and development continues in earlier-stage programs, including the Phase 2 OPAL trial in infants and toddlers with SMA, the newly initiated Phase 2 FORGE trial in FSHD, and a Phase 1 study of SRK-439 in healthy volunteers.
Scholar Rock Holding Corp director Jeffrey S. Flier reported open-market sales of 3,053 shares of Common Stock on July 1, 2026. The trades were executed at weighted average prices between about $52.96 and $55.01 per share under a pre-arranged Rule 10b-5-1 trading plan to cover tax obligations tied to vesting and settlement of restricted stock units. Following these transactions, the filing reports holdings consisting of 21,017 shares of common stock and 6,839 RSUs, indicating he retains a meaningful equity position in the company.
Scholar Rock Holding Corp director Michael Gilman sold 2,544 shares of common stock in open-market transactions on July 1, 2026. The sales were made under a Rule 10b-5-1 trading plan adopted on March 31, 2026 to cover tax obligations from vesting restricted stock units.
Prices ranged from about $52.97 to $55.01, reported as weighted average prices for each trade. After these transactions, Gilman holds 52,672 shares of common stock and 6,839 restricted stock units (RSUs), indicating he retains a substantial equity position in the company.
Scholar Rock Holding Corp director Kristina Burow reported routine insider sales tied to equity compensation. On July 1, 2026, she sold a total of 3,053 shares of common stock in open-market transactions at weighted average prices around $53–$54 per share. According to the filing, these trades were executed under a Rule 10b-5-1 trading plan adopted on March 31, 2026 to cover tax obligations from the vesting and settlement of restricted stock units (RSUs). After these transactions, she continues to hold 107,818 shares of common stock and 6,839 RSUs directly, and has an indirect interest in 2,345,711 shares held by ARCH Venture Fund VIII, L.P., over which she does not have voting or investment control and for which she disclaims beneficial ownership beyond any pecuniary interest.
Scholar Rock Holding Corp director Joshua Reed sold 3,053 shares of common stock in open-market transactions. The sales on July 1, 2026 were executed at weighted average prices of $53.4958 and $54.2814 per share under a pre-arranged Rule 10b5-1 trading plan. The filing notes the plan was adopted to cover tax obligations tied to the vesting and settlement of restricted stock units, indicating these are largely tax-related, scheduled sales. Following the transactions, Reed holds 19,518 equity-linked units, consisting of 12,679 shares of common stock and 6,839 RSUs.
Scholar Rock Holding Corp director Katie Peng reported selling 5,446 shares of common stock in open-market transactions on July 1, 2026. The sales were made under a Rule 10b5-1 trading plan adopted on March 20, 2026 to cover tax obligations from the vesting and settlement of restricted stock units.
After these transactions, Peng’s reported holdings consist of 21,500 shares of common stock and 12,801 RSUs, indicating she retains a meaningful equity stake tied to both current ownership and future vesting.
Mohammed Qatanani reports a proposed sale of 11,704 shares of Common Stock under a stock option exercise, proposed for 07/06/2026. The transaction is listed as to be executed through J.P. Morgan Securities LLC and denominated in cash.
The filing also lists a prior sale entry dated 04/06/2026 showing 11,704 shares in the "Securities Sold During The Past 3 Months" section. The filing is a Form 144 notice of a proposed resale; timing and proceeds treatment are those shown on the form.